论文部分内容阅读
目的探讨重组组织型纤溶酶原激活剂联合依达拉奉治疗急性脑梗死的临床疗效。方法将90例急性脑梗死患者随机分为治疗组和对照组,每组45例,对照组患者单纯给予重组组织型纤溶酶原激活剂(rt-PA)溶栓治疗,治疗组患者给予重组组织型纤溶酶原激活剂联合依达拉奉进行治疗。结果治疗组治疗总有效率为95.56%,显著高于对照组(68.89%),差异有统计学意义(P<0.01);治疗后,治疗组ADL指数评分和NIHSS评分改善更为显著,组间比较差异有统计学意义(P均<0.01)。结论急性脑梗死患者采用重组组织型纤溶酶原激活剂联合依达拉奉治疗不仅能够提高患者的临床疗效,降低患者的神经缺损程度,还可以促进患者日常生活活动能力的提高,进而改善了患者的生活质量,值得临床推广应用。
Objective To investigate the clinical effect of recombinant tissue plasminogen activator combined with edaravone in the treatment of acute cerebral infarction. Methods Ninety patients with acute cerebral infarction were randomly divided into treatment group and control group, 45 cases in each group. Patients in control group were given recombinant tissue plasminogen activator (rt-PA) thrombolytic therapy. Patients in treatment group were given recombinant Tissue plasminogen activator combined with edaravone for treatment. Results The total effective rate of the treatment group was 95.56%, significantly higher than that of the control group (68.89%), the difference was statistically significant (P <0.01). After treatment, ADL index score and NIHSS score of treatment group improved more significantly, The difference was statistically significant (P <0.01). Conclusion Recombinant tissue plasminogen activator combined with edaravone in patients with acute cerebral infarction can not only improve the clinical efficacy, reduce the degree of neurological deficit in patients, but also improve the activities of patients with daily activities, and then improve The quality of life of patients, it is worth clinical application.